Background: Sclerostin is a secreted Wnt inhibitor produced almost exclusively by osteocytes, which inhibits bone formation. Aromatase inhibitors (AIs), which reduce the conversion of steroids to estrogen, are used to treat endocrine-responsive breast cancer. As AIs lower estrogen levels, they increase bone turnover and lower bone mass. We analyzed changes in serum sclerostin levels in Korean women with breast cancer who were treated with an AI. Methods: We included postmenopausal women with endocrine-responsive breast cancer (n=90; mean age, 57.7 years) treated with an AI, and compared them to healthy premenopausal women (n=36; mean age, 28.0 years). The subjects were randomly as-signed to take either 5 mg alendronate with 0.5 µg calcitrio...
Background: Prospective studies have consistently found that postmenopausal breast cancer risk incre...
OBJECTIVE: Aromatase inhibitors (AI) treatment leads to an increased risk of bone loss and fractures...
INTRODUCTION: The bone mass benefits of anti-resorbers in postmenopausal osteoporosis are limited by...
BACKGROUND: Sclerostin is a secreted Wnt inhibitor produced almost exclusively by osteocytes, which ...
BackgroundSclerostin is a secreted Wnt inhibitor produced almost exclusively by osteocytes, which in...
Dept. of Medicine/석사Bone formation and resorption is a complicated pathway that is involved by many ...
Context: Studies in postmenopausal women have shown that estrogen reduces circulating sclerostin lev...
Aim: To determine the levels of Wnt inhibitors in patients treated with aromatase inhibitors (AIs) p...
Purpose: Arthralgia is the most common side effect in breast cancer patients receiving aromatase inh...
Objective: The aim of this study was to evaluate the impact of aromatase inhibitor (AI) treatment on...
Purpose: The positive effects of denosumab (DMAb) on bone mineral density (BMD) are quickly reversib...
International audienceBACKGROUND: The purpose of this study was to describe the fracture incidence a...
Summary Current treatments for postmenopausal osteopo-rosis suffer from side effects. Safe and natur...
Context: Aromatase deficiency causes obesity and insulin resistance in aromatase knockout mice and h...
Studies in postmenopausal women have shown that estrogen (E) reduces circulating ...
Background: Prospective studies have consistently found that postmenopausal breast cancer risk incre...
OBJECTIVE: Aromatase inhibitors (AI) treatment leads to an increased risk of bone loss and fractures...
INTRODUCTION: The bone mass benefits of anti-resorbers in postmenopausal osteoporosis are limited by...
BACKGROUND: Sclerostin is a secreted Wnt inhibitor produced almost exclusively by osteocytes, which ...
BackgroundSclerostin is a secreted Wnt inhibitor produced almost exclusively by osteocytes, which in...
Dept. of Medicine/석사Bone formation and resorption is a complicated pathway that is involved by many ...
Context: Studies in postmenopausal women have shown that estrogen reduces circulating sclerostin lev...
Aim: To determine the levels of Wnt inhibitors in patients treated with aromatase inhibitors (AIs) p...
Purpose: Arthralgia is the most common side effect in breast cancer patients receiving aromatase inh...
Objective: The aim of this study was to evaluate the impact of aromatase inhibitor (AI) treatment on...
Purpose: The positive effects of denosumab (DMAb) on bone mineral density (BMD) are quickly reversib...
International audienceBACKGROUND: The purpose of this study was to describe the fracture incidence a...
Summary Current treatments for postmenopausal osteopo-rosis suffer from side effects. Safe and natur...
Context: Aromatase deficiency causes obesity and insulin resistance in aromatase knockout mice and h...
Studies in postmenopausal women have shown that estrogen (E) reduces circulating ...
Background: Prospective studies have consistently found that postmenopausal breast cancer risk incre...
OBJECTIVE: Aromatase inhibitors (AI) treatment leads to an increased risk of bone loss and fractures...
INTRODUCTION: The bone mass benefits of anti-resorbers in postmenopausal osteoporosis are limited by...